Abstract:Background & aims: Although smoking is a leading risk factor for pancreatic ductal adenocarcinoma (PDAC), little is known about the mechanisms by which smoking promotes initiation or progression of PDAC. Methods: We studied the effects of nicotine administration on pancreatic cancer development in Kras(+/LSLG12Vgeo);Elas-tTA/tetO-Cre (Ela-KRAS) mice, Kras(+/LSLG12D);Trp53+/LSLR172H;Pdx-1-Cre (KPC) mice (which express constitutively active forms of KRAS), and C57/B6 mice. Mice were given nicotine for up to 86 weeks to produce blood levels comparable with those of intermediate smokers. Pancreatic tissues were collected and analyzed by immunohistochemistry and reverse transcriptase polymerase chain reaction; cells were isolated and assayed for colony and sphere formation and gene expression. The effects of nicotine were also evaluated in primary pancreatic acinar cells isolated from wild-type, nAChR7a(-/-), Trp53(-/-), and Gata6(-/-);Trp53(-/-) mice. We also analyzed primary PDAC cells that overexpressed GATA6 from lentiviral expression vectors. Results: Administration of nicotine accelerated transformation of pancreatic cells and tumor formation in Ela-KRAS and KPC mice. Nicotine induced dedifferentiation of acinar cells by activating AKT-ERK-MYC signaling; this led to inhibition of Gata6 promoter activity, loss of GATA6 protein, and subsequent loss of acinar differentiation and hyperactivation of oncogenic KRAS. Nicotine also promoted aggressiveness of established tumors as well as the epithelial-mesenchymal transition, increasing numbers of circulating cancer cells and their dissemination to the liver, compared with mice not exposed to nicotine. Nicotine induced pancreatic cells to acquire gene expression patterns and functional characteristics of cancer stem cells. These effects were markedly attenuated in K-Ras(+/LSL-G12D);Trp53(+/LSLR172H);Pdx-1-Cre mice given metformin. Metformin prevented nicotine-induced pancreatic carcinogenesis and tumor growth by up-regulating GATA6 and promoting differentiation toward an acinar cell program. Conclusions: In mice, nicotine promotes pancreatic carcinogenesis and tumor development via down-regulation of Gata6 to induce acinar cell dedifferentiation.

Supplemental Figure S2 from Nicotine Reduces Survival Via Augmentation of Paracrine HGF–MET Signaling in the Pancreatic Cancer Microenvironment

Supplemental Figure S1 from Nicotine Reduces Survival Via Augmentation of Paracrine HGF–MET Signaling in the Pancreatic Cancer Microenvironment

Nicotine Enhances Invasion and Metastasis of Human Colorectal Cancer Cells Through the Nicotinic Acetylcholine Receptor Downstream P38 MAPK Signaling Pathway.

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Activation of 5-Lipoxygenase is Required for Nicotine Mediated Epithelial-Mesenchymal Transition and Tumor Cell Growth

Figure S3 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Supplementary Figure 2 from BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs

Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and β-adrenergic receptor signaling pathways

Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice

Supplementary Figure 7 from BATF2 Deficiency Promotes Progression in Human Colorectal Cancer Via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs

Supplementary Figure 3 from BATF2 Deficiency Promotes Progression in Human Colorectal Cancer Via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Figure 1 from BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs

Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling

Supplementary Figure 6 from BATF2 Deficiency Promotes Progression in Human Colorectal Cancer Via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs

Supplementary Figure S7 from Chemotherapy-Induced miRNA-29c/Catenin-δ Signaling Suppresses Metastasis in Gastric Cancer

Supplementary Figure S6 from CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ

Supplementary Figure from IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment

Supplementary Figure 6 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Fig. 5 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Supplementary Figure 4 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776